1. Signaling Pathways
  2. Epigenetics
    Metabolic Enzyme/Protease
  3. Methionine Adenosyltransferase (MAT)

Methionine Adenosyltransferase (MAT)

S-adenosylmethionine Synthetase

Methionine adenosyltransferases (MATs), also known as S-Adenosylmethionine synthetase, are essential enzymes for life as they catalyzes the synthesis of one of the most important and pivotal biological molecules, S-adenosyl-methionine. S-adenosyl-methionine is the biological methyl donor required for a plethora of reactions within the cell.Mammalian systems express two genes, MAT1A and MAT2A, which encode for MATα1 and MATα2, the catalytic subunits of the MAT isoenzymes, respectively. A third gene MAT2B, encodes a regulatory subunit known as MATβ which controls the activity of MATα2. MAT1A, which is mainly expressed in hepatocytes, maintains the differentiated state of these cells, whilst MAT2A and MAT2B are expressed in extrahepatic tissues as well as non-parenchymal cells of the liver (e.g., hepatic stellate and Kupffer cells).

Methionine Adenosyltransferase (MAT) Related Products (23):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-108331
    3-TYP
    Inhibitor 99.96%
    3-TYP is an inhibitor of SIRT3 (IC50: ~377 μM) and an inhibitor of Methionine Adenosyltransferase (MAT) 2 and Indoleamine 2,3-Dioxygenase (IDO). There may be many off-target sites for 3-TYP that need to be examined, such as NAD-dependent enzymes, including dehydrogenases.
    3-TYP
  • HY-138630
    AG-270
    99.85%
    AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM.
    AG-270
  • HY-136144
    FIDAS-5
    98.88%
    FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities.
    FIDAS-5
  • HY-107778
    PF-9366
    99.98%
    PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC50 of 420 nM and a Kd of 170 nM.
    PF-9366
  • HY-112130
    AGI-24512
    Inhibitor 99.59%
    AGI-24512 is a potent methionine adenosyltransferase 2α (MAT2A) inhibitor, with an IC50 of 8 nM. AGI-24512 triggers DNA damage response. AGI-24512 can block proliferation of MTAP-deleted cancer cells in vitro. AGI-24512 can be used for researching anticancer.
    AGI-24512
  • HY-162353
    AZ'9567
    Inhibitor 99.21%
    AZ9567 is a potent MAT2A inhibitor. AZ9567 exhibits antiproliferative activity against MTAP KO HCT116 cells with a pIC50 of 8.9.
    AZ'9567
  • HY-159156
    MAT2A inhibitor 6
    Inhibitor
    MAT2A inhibitor 6 (Compound 3N-h) is a specific MAT2A inhibitor with oral activity and yellow fluorescence (IC50=26 nM), capable of visualizing MAT2A both in vitro and in vivo (λex = 430 nm, λem = 585 nm). MAT2A inhibitor 6 can induce apoptosis and has anticancer activity, which can be used in cancer research.
    MAT2A inhibitor 6
  • HY-163656
    MAT2A inhibitor 5
    Inhibitor
    MAT2A inhibitor 5(compound 39) is an orally active, selectivity and blood-brain permeability inhibitor of MAT2A with the IC50 of 11 nM. MAT2A inhibitor 5 inhibits tumor cell growth in vivo.
    MAT2A inhibitor 5
  • HY-139139
    MAT2A inhibitor 3
    99.27%
    MAT2A inhibitor 3 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1, compound 24, has an IC50 of <200 nM. MAT2A inhibitor 3 can be used for the research of cancers.
    MAT2A inhibitor 3
  • HY-112569
    MAT2A inhibitor 2
    99.71%
    MAT2A inhibitor 2 is an inhibitor of methionine adenosine transferase 2A (MAT2A) with oral activity. MAT2A inhibitor 2 can be used in osteoporosis study
    MAT2A inhibitor 2
  • HY-112131
    MAT2A inhibitor 1
    99.57%
    MAT2A inhibitor 1 is a methionine adenosyltransferase 2A (MATA2) inhibitor with an IC50 less than l00 nM.
    MAT2A inhibitor 1
  • HY-139536
    MAT2A inhibitor 4
    99.84%
    MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2 (MAT2A). MAT2A inhibitor 4 can be used for the research of cancer.
    MAT2A inhibitor 4
  • HY-112129
    AGI-25696
    AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.
    AGI-25696
  • HY-162135
    MAT2A-IN-14
    Inhibitor
    MAT2A-IN-14 (compound H3) is a MAT2A inhibitor, and generates reactive oxygen species after sonication to specifically degrade cellular MAT2A via rapid oxidative reactions. Combination of MAT2A-IN-14 and sonication induces 87% MAT2A depletion in human colon cancer cell.
    MAT2A-IN-14
  • HY-144184
    MAT2A-IN-6
    Inhibitor
    MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18).
    MAT2A-IN-6
  • HY-144185
    MAT2A-IN-7
    Inhibitor
    MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24).
    MAT2A-IN-7
  • HY-162010
    MAT2A-IN-13
    Inhibitor
    MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors treatment research.
    MAT2A-IN-13
  • HY-144181
    MAT2A-IN-5
    Inhibitor
    MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1).
    MAT2A-IN-5
  • HY-155149
    MAT2A-IN-12
    Inhibitor
    MAT2A Allosteric inhibitor 2 is a potent and selective MAT2A allosteric inhibitor with an IC50 of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC50=5 μM) in the the proliferation assay (MTAP-/- cell line).
    MAT2A-IN-12
  • HY-155148
    MAT2A-IN-11
    Inhibitor
    MAT2A Allosteric inhibitor 1 (compound 5) is a MAT2A selective inhibitor of methionine adenosyltransferase (MAT) with an IC50 of 6.8 nM.
    MAT2A-IN-11